Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 220-180-6 | CAS number: 2654-57-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Repeated dose toxicity: Oral
The No observed Adverse Effect level (NOAEL) for the test chemical is considered to be 316 mg/Kg bw.
Repeated dose toxicity: Inhalation
4-methyl-1-phenyl-3-pyrazolidone (CAS no 2654-57-1) has very low vapor pressure of 5.15E-09 hPa at 25 Deg C, so the potential for the generation of inhalable vapours is very low, also the normal conditions of use of this substance will not result in aerosols, particles or droplets of an inhalable size, so exposure to humans via the inhalatory route will be highly unlikely and therefore this end point for repeated dose toxicity by inhalation route of exposure was considered for waiver
Repeated dose toxicity: Dermal
The acute dermal toxicity value for 4-methyl-1-phenyl-3-pyrazolidone (CAS no 2654-57-1) (as provided in section 7.2.3) is >2000 mg/kg body weight. Considering this, the end point for repeated dermal toxicity is considered as waiver
Key value for chemical safety assessment
- Toxic effect type:
- dose-dependent
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- data from handbook or collection of data
- Remarks:
- Experimental data from various test chemicals
- Justification for type of information:
- Data for the target chemical is summarized based on data from various test chemicals
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Qualifier:
- according to guideline
- Guideline:
- other: Refer below principle
- Principles of method if other than guideline:
- WoE for the target CAS is summarized based on data from various test chemicals
- GLP compliance:
- not specified
- Limit test:
- no
- Species:
- rat
- Strain:
- other: 2. not specified; 3. Osborne Mendel rats
- Details on species / strain selection:
- No data
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- 2. No data
3. TEST ANIMALS
- Source: No data available
- Age at study initiation: Weanling rats
- Weight at study initiation: No data available
- Fasting period before study: No data available
- Housing: Animals were housed individually in wire cages.
- Diet (e.g. ad libitum): Ad libitum
- Water (e.g. ad libitum): Ad libitum
- Acclimatization period: No data available
ENVIRONMENTAL CONDITIONS
- Temperature (°C): No data available
- Humidity (%):No data available
- Air changes (per hr): No data available
- Photoperiod (hrs dark / hrs light): No data available
IN-LIFE DATES: From: To: No data available - Route of administration:
- oral: feed
- Details on route of administration:
- No data
- Vehicle:
- other: Feed
- Details on oral exposure:
- 2. PREPARATION OF DOSING SOLUTIONS: The test chemical was mixed with feed at dose level of 0, 2150, 3160, 4600, 6800, 10,000, 14,700 or 21,600 ppm (0, 215, 316, 460, 680, 1000, 1470 or 2160 mg/Kg)
DIET PREPARATION
- Rate of preparation of diet (frequency): No data
- Mixing appropriate amounts with (Type of food): No data
- Storage temperature of food: No data
VEHICLE
- Justification for use and choice of vehicle (if other than water): Feed
- Concentration in vehicle: 0, 2150, 3160, 4600, 6800, 10,000, 14,700 or 21,600 ppm (0, 215, 316, 460, 680, 1000, 1470 or 2160 mg/Kg)
- Amount of vehicle (if gavage): No data
- Lot/batch no. (if required): No data
- Purity: No data
3. PREPARATION OF DOSING SOLUTIONS: No data available
DIET PREPARATION
- Rate of preparation of diet (frequency): Weekly
- Mixing appropriate amounts with (Type of food): Details not specified.
- Storage temperature of food: No data available
VEHICLE
- Justification for use and choice of vehicle (if other than water): Feed
- Concentration in vehicle: 0, 1000, 2500 or 10000 ppm (0, 5, 125 or 500 mg/Kg bw)
- Amount of vehicle (if gavage): No data available
- Lot/batch no. (if required): No data available - Analytical verification of doses or concentrations:
- not specified
- Details on analytical verification of doses or concentrations:
- No data
- Duration of treatment / exposure:
- 2. Duration of treatment: 8 weeks
Duration of exposure: 7 weeks
3. 16 weeks - Frequency of treatment:
- Daily
- Remarks:
- 0, 2150, 3160, 4600, 6800, 10,000, 14,700 or 21,600 ppm (0, 215, 316, 460, 680, 1000, 1470 or 2160 mg/Kg) / 2
- Remarks:
- 0, 10000, 2500 or 1000 ppm (0, 500, 125 or 5 mg/Kg bw) / 3
- No. of animals per sex per dose:
- 2. Total: 40 males and 40 females
0 mg/Kg: 5 males and 5 females
215 mg/Kg: 5 males and 5 females
316 mg/Kg: 5 males and 5 females
460 mg/Kg: 5 males and 5 females
680 mg/Kg: 5 males and 5 females
1000 mg/Kg: 5 males and 5 females
1470 mg/Kg: 5 males and 5 females
2160 mg/Kg: 5 males and 5 females
3. Total: 80 animals
0 ppm: 10 males, 10 females
1000 ppm: 10 males, 10 females
2500 ppm: 10 males, 10 females
10000 ppm: 10 males, 10 females - Control animals:
- yes, concurrent vehicle
- Details on study design:
- No data
- Positive control:
- No data
- Observations and examinations performed and frequency:
- 2. CAGE SIDE OBSERVATIONS: Yes
- Time schedule: No data available
- Cage side observations checked in table [No.?] were included. Mortality
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Twice weekly
BODY WEIGHT: Yes
- Time schedule for examinations:No data available
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study): Yes, twice weekly
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: No data available
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: No data available
FOOD EFFICIENCY: No data available
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: No data available
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): No data available
- Time schedule for examinations:No data available
OPHTHALMOSCOPIC EXAMINATION: No data available
- Time schedule for examinations: No data available
- Dose groups that were examined: No data available
HAEMATOLOGY: NO data
- Time schedule for collection of blood: No data available
- Anaesthetic used for blood collection: No data available
- Animals fasted: No data available
- How many animals: No data available
- Parameters checked in table [No.?] were examined. No data
CLINICAL CHEMISTRY: No data
- Time schedule for collection of blood: No data available
- Animals fasted: No data available
- How many animals: No data available
- Parameters checked in table [No.?] were examined. No data
URINALYSIS: No data
- Time schedule for collection of urine: No data available
- Metabolism cages used for collection of urine: No data available
- Animals fasted: No data available
- Parameters checked in table [No.?] were examined. No data
NEUROBEHAVIOURAL EXAMINATION: No data available
- Time schedule for examinations: No data available
- Dose groups that were examined: No data available
- Battery of functions tested: sensory activity / grip strength / motor activity / other: No data available
OTHER: No data available
3. CAGE SIDE OBSERVATIONS: Yes
- Time schedule: Weekly
- Cage side observations checked in table [No.?] were included.
DETAILED CLINICAL OBSERVATIONS: No data available
- Time schedule: No data available
BODY WEIGHT: Yes
- Time schedule for examinations: Weekly
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study): Yes
- Food consumption for each animal determined and mean daily diet consumption calculated as gfood/kg body weight/day: Yes, weekly
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: No data available
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: No data available
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): No data available
- Time schedule for examinations: No data available
OPHTHALMOSCOPIC EXAMINATION: No data available
- Time schedule for examinations: No data available
- Dose groups that were examined: No data available
HAEMATOLOGY: Yes
- Time schedule for collection of blood: At 3, 6, 12 and 22 months
- Anaesthetic used for blood collection: No data available
- Animals fasted: No data available
- How many animals: On all animals included in the study.
- Parameters examined: White cell counts, red cell counts, haemoglobins and haematocrits.
CLINICAL CHEMISTRY: No data available
- Time schedule for collection of blood: No data available
- Animals fasted: No data available
- How many animals: No data available
- Parameters examined: No data available
URINALYSIS: No data available - Time schedule for collection of urine: No data available
- Metabolism cages used for collection of urine: No data available
- Animals fasted: No data available
- Parameters examined No data available
NEUROBEHAVIOURAL EXAMINATION: No data available
- Time schedule for examinations: No data available
- Dose groups that were examined: No data available
- Battery of functions tested: sensory activity / grip strength / motor activity / other: No data available
OTHER: No data available - Sacrifice and pathology:
- 2. GROSS PATHOLOGY: Yes, all surviving rats were sacrificed by necropsy
HISTOPATHOLOGY: No data
3. GROSS PATHOLOGY: Yes, Tissues of all the rats were examined macroscopically at the time of sacrifice. The viscera were removed and the liver, kidneys, spleen, heart, and testes were weighed.
HISTOPATHOLOGY: Yes, Liver, kidneys, spleen, heart, testes, abdominal and thoracic viscera, and one hind leg, for bone, bone marrow and muscle were preserved, embedded, sectioned and stained with haematoxylin eosin prior to microscopic examination. - Other examinations:
- No data
- Statistics:
- No data
- Clinical signs:
- not specified
- Mortality:
- no mortality observed
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- The mean body weight gain for males of the 4600 ppm dose group was 4% less than that of the control group. Female rats in the same dose group had a 4% increase in body weight gain when compared with the controls. At a dietary concentration of 6800 ppm, the mean body weight gain for males was 9% less than the controls; it was 1 % less for females of the 6800 ppm group when compared to the controls.
- Food consumption and compound intake (if feeding study):
- not specified
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not specified
- Haematological findings:
- not specified
- Clinical biochemistry findings:
- not specified
- Urinalysis findings:
- not specified
- Behaviour (functional findings):
- not specified
- Immunological findings:
- not specified
- Organ weight findings including organ / body weight ratios:
- not specified
- Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- 3. Slight hepatic cell swelling was noted and slight hyperkeratosis of squamous portion of the stomach at a dose of 500 mg/Kg bw
- Neuropathological findings:
- not specified
- Histopathological findings: non-neoplastic:
- not specified
- Histopathological findings: neoplastic:
- not specified
- Other effects:
- not specified
- Dose descriptor:
- NOAEL
- Remarks:
- 2
- Effect level:
- 316 mg/kg diet
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: No significant effects were noted at the mentioned dose level
- Dose descriptor:
- NOAEL
- Remarks:
- 3
- Effect level:
- 125 other: mg/Kg bw
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: No significant effects were noted at the mentioned dose level
- Critical effects observed:
- not specified
- Conclusions:
- The No observed Adverse Effect level (NOAEL) for the test chemical is considered to be 316 mg/Kg bw.
- Executive summary:
Data available for the various test chemicals was reviewed to determine the toxic nature of the test chemical. The studies are as mentioned below:
Subchronic repeated dose oral toxicity study was performed to determine toxic nature of the test chemical. The study was performed using 5 male and 5 female rats at dose level of 0, 2150, 3160, 4600, 6800, 10,000, 14,700 or 21,600 ppm (0, 215, 316, 460, 680, 1000, 1470 or 2160 mg/Kg). The rats were given treated feed for 7 weeks and untreated feed for 1 week; controls were fed control diet for 8 weeks. Body weights and feed consumption for all rats were measured twice weekly, At the end of the study, all surviving rats were sacrificed for necropsy. The mean body weight gain for males of the 4600 ppm dose group was 4% less than that of the control group. Female rats in the same dose group had a 4% increase in body weight gain when compared with the controls. At a dietary concentration of 6800 ppm, the mean body weight gain for males was 9% less than the controls; it was 1 % less for females of the 6800 ppm group when compared to the controls. No deaths occurred in any dosed group. One female control rat died on study. Based on the observations made, the No observed Adverse Effect level (NOAEL) for the test chemical is considered to be 316 mg/Kg bw.
In another study, Chronic toxicity oral study for the test compound cinnamic aldehyde was studied in male and female Osborne-Mendel rats. The test compound was fed through the diet at a concentration of 0, 100, 2500 or 10000 ppm (0, 5, 125 or 500 mg/Kg bw). No effects were noted on microscopic examination at 125 mg/KG bw. Slight hepatic cell swelling was noted and slight hyperkeratosis of squamous portion of the stomach at a dose level of 500 mg/Kg bw. The No observed Adverse Effect Level (NOAEL) for the test compound cinnamaic aldehyde in Osborne-
Mendel rats is found to be 125 mg/Kg bw.
Based on the observations made, the No observed Adverse Effect level (NOAEL) for the test chemical is considered to be 316 mg/Kg bw.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 316 mg/kg bw/day
- Study duration:
- subchronic
- Experimental exposure time per week (hours/week):
- 24
- Species:
- rat
- Quality of whole database:
- Data is from K2 source
Repeated dose toxicity: inhalation - systemic effects
Link to relevant study records
- Endpoint:
- repeated dose toxicity: inhalation, other
- Data waiving:
- other justification
- Justification for data waiving:
- other:
Reference
Endpoint conclusion
- Endpoint conclusion:
- no study available
- Quality of whole database:
- Waiver
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Link to relevant study records
- Endpoint:
- repeated dose toxicity: dermal, other
- Data waiving:
- other justification
- Justification for data waiving:
- other:
Reference
Endpoint conclusion
- Endpoint conclusion:
- no study available
- Quality of whole database:
- Waiver
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Data available for the various test chemicals was reviewed to determine the toxic nature of the test chemical. The studies are as mentioned below:
Repeated dose toxicity: Oral
Data available for the various test chemicals was reviewed to determine the toxic nature of the test chemical. The studies are as mentioned below:
Subchronic repeated dose oral toxicity study was performed to determine toxic nature of the test chemical. The study was performed using 5 male and 5 female rats at dose level of 0, 2150, 3160, 4600, 6800, 10,000, 14,700 or 21,600 ppm (0, 215, 316, 460, 680, 1000, 1470 or 2160 mg/Kg). The rats were given treated feed for 7 weeks and untreated feed for 1 week; controls were fed control diet for 8 weeks. Body weights and feed consumption for all rats were measured twice weekly, At the end of the study, all surviving rats were sacrificed for necropsy. The mean body weight gain for males of the 4600 ppm dose group was 4% less than that of the control group. Female rats in the same dose group had a 4% increase in body weight gain when compared with the controls. At a dietary concentration of 6800 ppm, the mean body weight gain for males was 9% less than the controls; it was 1 % less for females of the 6800 ppm group when compared to the controls. No deaths occurred in any dosed group. One female control rat died on study. Based on the observations made, the No observed Adverse Effect level (NOAEL) for the test chemical is considered to be 316 mg/Kg bw.
In another study, Chronic toxicity oral study for the test compound cinnamic aldehyde was studied in male and female Osborne-Mendel rats. The test compound was fed through the diet at a concentration of 0, 100, 2500 or 10000 ppm (0, 5, 125 or 500 mg/Kg bw). No effects were noted on microscopic examination at 125 mg/KG bw. Slight hepatic cell swelling was noted and slight hyperkeratosis of squamous portion of the stomach at a dose level of 500 mg/Kg bw. The No observed Adverse Effect Level (NOAEL) for the test compound cinnamaic aldehyde in Osborne-
Mendel rats is found to be 125 mg/Kg bw.
Based on the observations made, the No observed Adverse Effect level (NOAEL) for the test chemical is considered to be 316 mg/Kg bw.
Repeated dose toxicity: Inhalation
4-methyl-1-phenyl-3-pyrazolidone (CAS no 2654-57-1) has very low vapor pressure of 5.15E-09 hPa at 25 Deg C, so the potential for the generation of inhalable vapours is very low, also the normal conditions of use of this substance will not result in aerosols, particles or droplets of an inhalable size, so exposure to humans via the inhalatory route will be highly unlikely and therefore this end point for repeated dose toxicity by inhalation route of exposure was considered for waiver.
Repeated dose toxicity: Dermal
The acute dermal toxicity value for 4-methyl-1-phenyl-3-pyrazolidone (CAS no 2654-57-1) (as provided in section 7.2.3) is >2000 mg/kg body weight. Considering this, the end point for repeated dermal toxicity is considered as waiver.
Based on the data available for the test chemicals and applying weight of evidence approach, the test chemical is not likely to classify as a toxicant upon repeated exposure by oral, dermal and inhalation route of exposure as per the criteria mentioned in CLP regulation.
Justification for classification or non-classification
Based on the data available for the test chemicals and applying weight of evidence approach, the test chemical is not likely to classify as a toxicant upon repeated exposure by oral, dermal and inhalation route of exposure as per the criteria mentioned in CLP regulation.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.